期刊文献+

从“虚”论治晚期非小细胞肺癌 被引量:1

"Deficiency" in Treating Advanced Non-Small Cell Lung Cancer
下载PDF
导出
摘要 治疗癌症是目前医疗工作者所面临的重要难题,随着人口老龄化的到来和人们生活方式的改变,现代化进程的弊端,癌症的发病率和死亡率呈上升趋势,而发病年龄也呈年轻化趋势。其中肺癌对人类健康与生命健康的危害非常严重[1]。其临床分型主要为小细胞和非小细胞癌,后者占较高比重。对癌症的治疗因其早期发现的几率低,且其发病原因尚未明了,临床上大多数的癌症患者错过了手术的最佳时期,导致治疗的不及时,而影响其治疗效果和生活质量[3]。中医对此病的病因病机可概括为正虚不能抗邪,故本文主要从"虚"论治晚期非小细胞肺癌。 Treatment of cancer is the important problem that medical workers are facing, with the population aging and the change of people's lifestyles, and drawbacks of the process of modernization, the incidence and mortality of cancer are increasing, and the age of onset tends to be younger. Lung cancer is seriously harmful to human health and life. Clinical classification is divided into small cell cancer and non-small cell cancer, and the latter accounts for a high proportion. Because of low probability of earlier detection and unclear etiology, clinically, most cancer patients missed the best time of surgery. This resulted in an overdue treatment, and affected the outcome of treatment and quality of life. The etiology and pathogenesis of TCM of this disease can be generalized as positive deficiency can not resist evil, so this article mainly discussed treatment from " deficiency" on advanced non-small cell lung cancer.
作者 旋静 连树林
出处 《中国中医药现代远程教育》 2015年第10期1-2,共2页 Chinese Medicine Modern Distance Education of China
关键词 中医药 从“虚”论治 晚期非小细胞肺癌 traditional Chinese medicine treatment from " deficiency" advanced non-small cell lung cancer
  • 相关文献

参考文献5

二级参考文献50

  • 1鄢践.实体瘤疗效评定最新指南[J].国外医学·肿瘤分册,2000,27(6):375-375.
  • 2Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2007 [J]. CA Cancer J Clin, 2007, 57:43-66.
  • 3Fry WA, Phillips JL, Menck HR. Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report [J]. Cancer, 1999, 86:1867-76.
  • 4Mareelo P, Eduardo C, Clarissa T. Development and validation of the Portuguese version of the WHOQOL-OLD module [ J]. Rev Saude Publica, 2006, 40 (5) : 785 -91.
  • 5Oken MM, Creen RH, Tormey DC, etc. Toxicity and response criteria of the Eastern Cooperative Oncology Group [ J]. Am J Clin Oncol, 1982, 5 (6): 649-55.
  • 6Gandara DR, Lara PN Jr, Goldberg Z, et al. Neoadjuvant therapy for non-small cell lung cancer [J]. Antieancer Drugs, 2001;12 (Suppll): 5 -9.
  • 7Lim WT, Tan EH,Toh CK,et al. Phase I pharmacoki-netic study of a weekly liposomal paclitaxel formulation(Genexol-PM)in patients with solid tumors[J] .Ann Oneol, 2010;21 (2) :382 - 388.
  • 8FosseUa F, Pereira JR, yon Pawel J, et aL Randomized, multinational, phaseⅢ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group[J]. J Clin Oncol, 2003;21(16) : 3016-3024.
  • 9Milross CG, Mason KA, Hunter NR, et al. Relationship of mitotic arrest and apoptosis to antitumor effect of paclitaxel [J]. J Nat I Cancer Inst, 1996;88(18) : 1308 - 1314.
  • 10Chu Q, V'mcent M, Logan D, et al. Lung Cancer Disease Site Group of Cancer Care Ontario' s Program in Evidence-based Care.Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline [J]. Lung Cancer, 2005;50(3) : 355 -374.

共引文献104

同被引文献17

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部